Anthony R Chao

age ~32

from Richmond, CA

Get Report

Also known as:

Minghua Chao

Connected to:

Anthony Chao Phones & Addresses

Richmond, CA
Union City, CA
Gatlinburg, TN
San Leandro, CA
San Diego, CA
Fremont, CA

Us Patents

Cell-Based Multiplexing Adme Analysis Using Focused Fluid Flow
view source
US Patent:

20030044992, Mar 6, 2003
Filed:

Aug 31, 2001
Appl. No.:

09/945360
Inventors:

Anthony Chao - Cupertino CA, US
Martin Kirk - San Carlos CA, US
International Classification:

G01N035/08
US Classification:

436/052000, 436/063000, 422/068100, 422/081000, 422/102000, 435/004000, 435/029000
Abstract:

The invention relates to methods and devices for conducting multiplex assays for determining absorption, distribution, metabolism, and/or excretion (ADME) properties of an analyte. The method and device provide the ability to study analytes by controllably flowing, in laminar flow, an analyte in an analyte stream over a substrate having a plurality of substantially parallel individual test lanes on the surface thereof, wherein each test lane comprises a plurality of living cells immobilized therein. Changes, when present, in the analyte, the cells, or both, are detected and thereafter correlated to an ADME property of the analyte.

Formulation And Dosage Form For Increasing Oral Bioavailability Of Hydrophilic Macromolecules
view source
US Patent:

20030198619, Oct 23, 2003
Filed:

Dec 18, 2002
Appl. No.:

10/324154
Inventors:

Liang Dong - Sunnyvale CA, US
Patrick Wong - Burlingame CA, US
Vu Nguyen - San Jose CA, US
Si-Hong Yum - Belmont CA, US
Anthony Chao - Cupertino CA, US
Peter Daddona - Menlo Park CA, US
International Classification:

A61K038/28
A61K038/21
A61K038/43
A61K031/715
A61K038/13
US Classification:

424/085700, 424/094100, 514/012000, 514/003000, 514/054000, 514/011000
Abstract:

The present invention includes a formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules. The formulation of the present invention includes a permeation enhancer, a hydrophilic macromolecule, and a carrier that exhibits in-situ gelling properties, such as a nonionic surfactant. The formulation of the present invention is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation of the present invention presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. The dosage form of the present invention incorporates the formulation of the present invention and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time.

Formulation And Dosage Form For Increasing Oral Bioavailability Of Hydrophilic Macromolecules
view source
US Patent:

20090087484, Apr 2, 2009
Filed:

Sep 28, 2007
Appl. No.:

11/864017
Inventors:

Liang C. DONG - Sunnyvale CA, US
Patrick S. L. WONG - Burlingame CA, US
Vu A. NGUYEN - San Jose CA, US
Si-Hong Alicia Yum - Belmont CA, US
Anthony C. CHAO - Cupertino CA, US
Peter E. Daddona - Menlo Park CA, US
Assignee:

ALZA CORPORATION - Mountain View CA
International Classification:

A61K 31/20
A61K 31/70
A61K 38/00
A61K 38/21
A61K 38/43
A61K 47/00
A61K 9/48
A61K 9/52
A61P 1/00
US Classification:

424452, 424457, 424 857, 424 941, 514 12, 514 2, 514 23, 514558, 514 56, 5147724, 514773, 514777, 514784
Abstract:

A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. A dosage form incorporates the formulation and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time.